Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 4/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.35 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12258418 | 0.90 | BRD4 (0.39) | BRD4ALKCDK2FGFR4HTR6 | |
| SCHEMBL1883574 | 0.85 | BRD4 (0.44) | BRD4PTGDR2ALKCDK2HTR6 | |
| SCHEMBL2544624 | 0.75 | CYP3A4 (0.53) | CDK2JAK3 | |
| SCHEMBL1885308 | 0.74 | HTR6 (0.40) | BRD4ALKCDK2HTR6CCNE1 | |
| SCHEMBL1267361 | 0.74 | HTR6 (0.40) | BRD4ALKCDK2HTR6CCNE1 | |
| SCHEMBL4512514 | 0.72 | MAPT (0.43) | BRD4CDK2HTR6CCNE1 | |
| SCHEMBL1268147 | 0.71 | HTR6 (0.57) | PTGDR2ALKCDK2HTR6CCNE1 | |
| SCHEMBL3947254 | 0.70 | HTR6 (0.39) | BRD4ALKCDK2HTR6CCNE1 | |
| SCHEMBL12675766 | 0.70 | HTR6 (0.39) | BRD4ALKCDK2HTR6CCNE1 | |
| SCHEMBL2111701 | 0.70 | HTR6 (0.41) | BRD4ALKCDK2HTR6CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283423-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170283423-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2017-10-05 | — | — | US | disclosed |
| EP-2560972-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9682981-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682981-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150183793-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2015-07-02 | — | — | US | disclosed |
| US-20150183793-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2015-07-02 | — | — | US | disclosed |
| US-8901118-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901118-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2560972-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011133637-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133637-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, NTRK1, PRKDC | BRD4 4349/4885PTGDR2 2027/4885ALK 118/4885 |
| US-20170283423-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, PRKDC, NTRK1 | BRD4 4399/4885PTGDR2 1937/4885ALK 158/4885 |
| US-20150183793-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, PRKDC, NTRK1 | BRD4 4330/4885PTGDR2 1940/4885ALK 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.